New Insights into the Combinability of Eloxation® (Oxaliplatin): Present and Future Prospects

Raymond E , Chaney SG , Taamma A et al: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9 (10): 1053–1071.

Zelek L , Cottu P , Tubiana-Hulin M et al: Phase II study of oxaliplatin and fluorouracil in taxane and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002; 20 (10): 2551–2558.

Faivre S , Raymond E , Woynarowski JM et al: Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44 (2): 117–123.

Louvet C , Andre T , Lledo G et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20 (6): 1512–1518.

Alberts SR , Townley P , Cha SS et al: Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma: a NCCTG phase II study. Proc ASCO 2002; 21: abst 501.

Faivre S , Le Chevalier T ; Monnerat C et al: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13 (9): 1479–1489.

Aschele C , Friso ML , Pucciarelli S et al: A phase l-ll study of oxaliplatin, 5FU continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Proc ASCO 2002; 21: abst 527.

Tabernero J , Butts CA , Cassidy J et al: Capecitabine and oxaliplatin in combination as first line therapy for patients with metastatic colorectal cancer: results of an International multicenter phase ii trial. Proc ASCO 2002; 21: abst 531.

Garufi C , Nistico C , Brienza S et al: Single-agent oxaliplatin in pretreated advanced breast cancer patients. A phase II study. Ann Oncol 2001; 12 (2):179–182.